Interestingly, in molecularly annotated ET patients at diagnosis, the JAK2V617F mutated patients have more circulating EVs and higher levels of EVs with procoagulant activity than the Calreticulin-mutated and triple negative counterparts. The gene discussed is CALR; the disease is essential thrombocythemia.